Investment Opportunities in Abivax and Nektar Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 20 2026
0mins
Should l Buy ABVX?
Source: Fool
- Potential Blockbuster for Abivax: Abivax is developing obefazimod for chronic inflammatory diseases, currently in phase 3 trials for ulcerative colitis, with top-line data expected in Q2; if successful, it could lead to regulatory approval and tap into a market projected to reach $14.3 billion by 2035.
- Acquisition Rumors Boost Stock: Despite a 10% decline this year, Abivax's stock has surged over 1,900% in the past year, driven by strong clinical results and acquisition rumors from Eli Lilly and AstraZeneca, suggesting that a buyout could occur at a premium to current prices.
- Strong Cash Position: As of Q3 2025, Abivax reported €589.7 million (approximately $697 million) in cash, sufficient to fund operations into Q4 2027, indicating robust financial health.
- Nektar's Promising Therapy: Nektar's rezpegaldesleukin showed over 80% of patients achieving at least 75% skin improvement in a phase 2b trial for moderate-to-severe atopic dermatitis, positioning it as a strong competitor in the eczema market against established therapies like Dupixent.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABVX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABVX
Wall Street analysts forecast ABVX stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 102.470
Low
131.00
Averages
150.71
High
175.00
Current: 102.470
Low
131.00
Averages
150.71
High
175.00
About ABVX
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investment Outlook for Healthcare Stocks
- Moderna's mRNA Platform: Moderna's mRNA vaccines are favored for their rapid production and strong immune responses, particularly with its flu vaccine seeking U.S. approval, which is expected to enhance market competitiveness and drive future growth.
- Personalized Cancer Vaccine Progress: The mRNA-4157, developed in partnership with Merck, shows promising results in significantly reducing recurrence or death risk in advanced melanoma patients, with five-year follow-up data indicating optimistic clinical prospects that could sustain stock price growth over the next five years.
- Abivax's Innovative Drug: Abivax's obefazimod demonstrates excellent efficacy in treating ulcerative colitis, with clinical trials showing that 47.3% of patients previously unresponsive to traditional treatments could benefit, positioning the company to challenge market giants and achieve sales growth if approved.
- Market Competition and Risks: While Abivax faces fierce competition from large pharmaceutical companies, the unique advantages of obefazimod may allow it to capture market share over the next five years; however, the risks associated with clinical trials require cautious consideration from investors.
See More
Biotech Companies Show Promising Clinical Progress
- Moderna's mRNA Platform: Moderna's mRNA vaccines are produced faster than traditional vaccines and elicit stronger immune responses, with shares up 73% in 2023, indicating potential for continued growth over the next five years despite clinical and regulatory risks.
- Personalized Cancer Vaccine: The mRNA-4157 candidate, when combined with Keytruda, significantly reduced recurrence or death risk in advanced melanoma patients, showcasing its potential across various cancer types and likely enhancing future market performance for Moderna.
- Abivax's Innovative Drug: Abivax's obefazimod achieved its primary endpoint of clinical remission in a phase 3 trial, with 47.3% of patients previously treated unsuccessfully, positioning it as a strong competitor in the ulcerative colitis market, challenging established players if approved.
- Market Potential and Risks: If Abivax secures approval for obefazimod and expands into related conditions, its sales could soar over the next five years, but investors should remain cautious of potential clinical trial setbacks that could impact stock performance.
See More
Abivax CEO: No Rush for Deals Ahead of Key Trial
- Cautious Financial Outlook: Abivax CEO Marc de Garidel indicated that the company is not rushing into deals ahead of a pivotal Phase 3 trial readout expected in late Q2 2026, suggesting a strategic decision to wait for better terms in potential partnerships.
- Capital Raising Plans: De Garidel revealed that the company is likely to raise several million dollars through a combination of equity and debt after the trial readout, aiming for a capital influx by late June to support its path to profitability.
- Market Rollout Strategy: Following positive trial data, Abivax plans to seek partners for the market launch of obefazimod outside the U.S., demonstrating confidence in the drug's potential and an openness to external collaborations for commercialization.
- Executive Changes: Abivax announced the appointment of Michael Nesrallah as Chief Commercial Officer and Keith Fournier as Senior Vice President of Global Regulatory Affairs, reflecting strategic adjustments in its leadership team to bolster future business initiatives.
See More
Abivax Reports €530.4M Cash Position for 2025
- Cash Position: As of December 31, 2025, Abivax reported cash, cash equivalents, and short-term investments totaling €530.4 million, providing a projected cash runway into Q4 2027 based on current operating assumptions, ensuring financial stability for the company in the coming years.
- R&D Expense Increase: Research and development expenses rose to €177.8 million in 2025, accounting for 70.9% of operating expenses, compared to €146.5 million (79.0% of operating expenses) in 2024, indicating the company's ongoing commitment to drug development and strategic focus.
- Market Reaction: Despite maintaining a 'Strong Buy' rating amid buyout speculation, Abivax's stock price declined after denying acquisition rumors with AstraZeneca, reflecting market attention on the company's fundamentals.
- Analyst Ratings: Seeking Alpha's Quant Rating on Abivax indicates a positive outlook for the company's future, particularly regarding the advancement of Obefazimod, potentially providing further confidence to investors.
See More
Investment Opportunities in Abivax and Nektar Therapeutics
- Potential Blockbuster for Abivax: Abivax is developing obefazimod for chronic inflammatory diseases, currently in phase 3 trials for ulcerative colitis, with top-line data expected in Q2; if successful, it could lead to regulatory approval and tap into a market projected to reach $14.3 billion by 2035.
- Acquisition Rumors Boost Stock: Despite a 10% decline this year, Abivax's stock has surged over 1,900% in the past year, driven by strong clinical results and acquisition rumors from Eli Lilly and AstraZeneca, suggesting that a buyout could occur at a premium to current prices.
- Strong Cash Position: As of Q3 2025, Abivax reported €589.7 million (approximately $697 million) in cash, sufficient to fund operations into Q4 2027, indicating robust financial health.
- Nektar's Promising Therapy: Nektar's rezpegaldesleukin showed over 80% of patients achieving at least 75% skin improvement in a phase 2b trial for moderate-to-severe atopic dermatitis, positioning it as a strong competitor in the eczema market against established therapies like Dupixent.
See More
Abivax Viewed as a Potential Acquisition Target
- Drug Development Outlook: Abivax's lead drug candidate, obefazimod, is undergoing a phase 3 trial for moderately to severely active ulcerative colitis, with top-line data expected in Q2; if successful, it could lead to the company's first approved therapy, tapping into a market projected to reach $14.3 billion by 2035.
- Strong Financial Position: As of Q3 2025, Abivax reported €589.7 million (approximately $697 million) in cash and cash equivalents, sufficient to fund operations into Q4 2027, indicating robust financial health during its clinical stage.
- Market Competitiveness: Despite a 10% decline in Abivax's stock this year, it has surged over 1,900% in the past year, primarily driven by positive clinical trial results and acquisition rumors from pharma giants Eli Lilly and AstraZeneca, reflecting high market expectations for its future.
- Nektar's Growth Potential: Nektar Therapeutics' rezpegaldesleukin showed promising results in its phase 2b trial for moderate-to-severe atopic dermatitis, with over 80% of patients achieving at least 75% skin improvement at 36 weeks, positioning it as a strong competitor and potential acquisition target for larger pharmaceutical companies.
See More
Investment Outlook for Healthcare Stocks
- Moderna's mRNA Platform: Moderna's mRNA vaccines are favored for their rapid production and strong immune responses, particularly with its flu vaccine seeking U.S. approval, which is expected to enhance market competitiveness and drive future growth.
- Personalized Cancer Vaccine Progress: The mRNA-4157, developed in partnership with Merck, shows promising results in significantly reducing recurrence or death risk in advanced melanoma patients, with five-year follow-up data indicating optimistic clinical prospects that could sustain stock price growth over the next five years.
- Abivax's Innovative Drug: Abivax's obefazimod demonstrates excellent efficacy in treating ulcerative colitis, with clinical trials showing that 47.3% of patients previously unresponsive to traditional treatments could benefit, positioning the company to challenge market giants and achieve sales growth if approved.
- Market Competition and Risks: While Abivax faces fierce competition from large pharmaceutical companies, the unique advantages of obefazimod may allow it to capture market share over the next five years; however, the risks associated with clinical trials require cautious consideration from investors.
See More
Biotech Companies Show Promising Clinical Progress
- Moderna's mRNA Platform: Moderna's mRNA vaccines are produced faster than traditional vaccines and elicit stronger immune responses, with shares up 73% in 2023, indicating potential for continued growth over the next five years despite clinical and regulatory risks.
- Personalized Cancer Vaccine: The mRNA-4157 candidate, when combined with Keytruda, significantly reduced recurrence or death risk in advanced melanoma patients, showcasing its potential across various cancer types and likely enhancing future market performance for Moderna.
- Abivax's Innovative Drug: Abivax's obefazimod achieved its primary endpoint of clinical remission in a phase 3 trial, with 47.3% of patients previously treated unsuccessfully, positioning it as a strong competitor in the ulcerative colitis market, challenging established players if approved.
- Market Potential and Risks: If Abivax secures approval for obefazimod and expands into related conditions, its sales could soar over the next five years, but investors should remain cautious of potential clinical trial setbacks that could impact stock performance.
See More
Abivax CEO: No Rush for Deals Ahead of Key Trial
- Cautious Financial Outlook: Abivax CEO Marc de Garidel indicated that the company is not rushing into deals ahead of a pivotal Phase 3 trial readout expected in late Q2 2026, suggesting a strategic decision to wait for better terms in potential partnerships.
- Capital Raising Plans: De Garidel revealed that the company is likely to raise several million dollars through a combination of equity and debt after the trial readout, aiming for a capital influx by late June to support its path to profitability.
- Market Rollout Strategy: Following positive trial data, Abivax plans to seek partners for the market launch of obefazimod outside the U.S., demonstrating confidence in the drug's potential and an openness to external collaborations for commercialization.
- Executive Changes: Abivax announced the appointment of Michael Nesrallah as Chief Commercial Officer and Keith Fournier as Senior Vice President of Global Regulatory Affairs, reflecting strategic adjustments in its leadership team to bolster future business initiatives.
See More
Abivax Reports €530.4M Cash Position for 2025
- Cash Position: As of December 31, 2025, Abivax reported cash, cash equivalents, and short-term investments totaling €530.4 million, providing a projected cash runway into Q4 2027 based on current operating assumptions, ensuring financial stability for the company in the coming years.
- R&D Expense Increase: Research and development expenses rose to €177.8 million in 2025, accounting for 70.9% of operating expenses, compared to €146.5 million (79.0% of operating expenses) in 2024, indicating the company's ongoing commitment to drug development and strategic focus.
- Market Reaction: Despite maintaining a 'Strong Buy' rating amid buyout speculation, Abivax's stock price declined after denying acquisition rumors with AstraZeneca, reflecting market attention on the company's fundamentals.
- Analyst Ratings: Seeking Alpha's Quant Rating on Abivax indicates a positive outlook for the company's future, particularly regarding the advancement of Obefazimod, potentially providing further confidence to investors.
See More
Investment Opportunities in Abivax and Nektar Therapeutics
- Potential Blockbuster for Abivax: Abivax is developing obefazimod for chronic inflammatory diseases, currently in phase 3 trials for ulcerative colitis, with top-line data expected in Q2; if successful, it could lead to regulatory approval and tap into a market projected to reach $14.3 billion by 2035.
- Acquisition Rumors Boost Stock: Despite a 10% decline this year, Abivax's stock has surged over 1,900% in the past year, driven by strong clinical results and acquisition rumors from Eli Lilly and AstraZeneca, suggesting that a buyout could occur at a premium to current prices.
- Strong Cash Position: As of Q3 2025, Abivax reported €589.7 million (approximately $697 million) in cash, sufficient to fund operations into Q4 2027, indicating robust financial health.
- Nektar's Promising Therapy: Nektar's rezpegaldesleukin showed over 80% of patients achieving at least 75% skin improvement in a phase 2b trial for moderate-to-severe atopic dermatitis, positioning it as a strong competitor in the eczema market against established therapies like Dupixent.
See More
Abivax Viewed as a Potential Acquisition Target
- Drug Development Outlook: Abivax's lead drug candidate, obefazimod, is undergoing a phase 3 trial for moderately to severely active ulcerative colitis, with top-line data expected in Q2; if successful, it could lead to the company's first approved therapy, tapping into a market projected to reach $14.3 billion by 2035.
- Strong Financial Position: As of Q3 2025, Abivax reported €589.7 million (approximately $697 million) in cash and cash equivalents, sufficient to fund operations into Q4 2027, indicating robust financial health during its clinical stage.
- Market Competitiveness: Despite a 10% decline in Abivax's stock this year, it has surged over 1,900% in the past year, primarily driven by positive clinical trial results and acquisition rumors from pharma giants Eli Lilly and AstraZeneca, reflecting high market expectations for its future.
- Nektar's Growth Potential: Nektar Therapeutics' rezpegaldesleukin showed promising results in its phase 2b trial for moderate-to-severe atopic dermatitis, with over 80% of patients achieving at least 75% skin improvement at 36 weeks, positioning it as a strong competitor and potential acquisition target for larger pharmaceutical companies.
See More
